Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509853 | 0.89 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL14461916 | 0.83 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL12426159 | 0.78 | TGFBR1 (0.64) | NPC1RAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL12426337 | 0.77 | DHPS (0.41) | NPC1RAB9ASMN1; SMN2NR1I3DHPS | |
| SCHEMBL12426299 | 0.73 | MAPT (0.45) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12426318 | 0.73 | TNKS (0.48) | NPC1RAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL10589866 | 0.72 | IDO1 (0.57) | NPC1RAB9ASMN1; SMN2NR1I3TP53 | |
| SCHEMBL8357919 | 0.71 | DHFR (0.52) | NR1I3DHPSTP53MAPTIDH1 | |
| SCHEMBL31044873 | 0.71 | ADORA2A (0.43) | KMT2ANR1I3DHPSTP53MAPT | |
| SCHEMBL3124020 | 0.71 | KDR (0.54) | NPC1RAB9ASMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | NPC1 2421/4885RAB9A 2932/4885SMN1; SMN2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.